SOPHiA GENETICS (NASDAQ:SOPH) Insider Manuela Valente Sells 4,241 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 4,241 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.05, for a total transaction of $21,417.05. Following the transaction, the insider directly owned 210,450 shares of the company’s stock, valued at approximately $1,062,772.50. This represents a 1.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Monday, April 20th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total transaction of $1,976.00.
• On Wednesday, April 8th, Manuela Valente sold 3,824 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total value of $18,546.40.

SOPHiA GENETICS Trading Up 1.9%

SOPH traded up $0.10 on Tuesday, reaching $5.44. 284,563 shares of the company’s stock were exchanged, compared to its average volume of 187,273. SOPHiA GENETICS SA has a twelve month low of $2.92 and a twelve month high of $6.30. The company’s 50 day moving average is $5.12 and its 200-day moving average is $4.96. The company has a market cap of $456.36 million, a price-to-earnings ratio of -10.46 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC raised its stake in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the period. Archon Capital Management LLC grew its stake in SOPHiA GENETICS by 3.4% during the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after buying an additional 14,342 shares during the last quarter. Finally, Hodges Capital Management Inc. bought a new stake in SOPHiA GENETICS during the 1st quarter worth about $2,157,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Negative Sentiment: Chairman Jurgi Camblong sold 22,486 shares under a pre-arranged Rule 10b5-1 plan, and several other executives also sold stock the same day, including the CEO, CFO, CTO, and other insiders. While these sales were reportedly tied to tax withholding from vested equity awards, the breadth of selling can still pressure investor sentiment. Article: Chairman Jurgi Camblong sale filing
• Neutral Sentiment: The insider transactions were disclosed as routine 10b5-1 sales related to equity-award vesting, which makes them less concerning than discretionary selling, but they still add noise around the stock. Article: Philippe Menu sale filing
• Neutral Sentiment: SOPHiA GENETICS previously reported quarterly revenue of $21.69 million, topping expectations, even though earnings missed estimates. That mixed report still supports the stock’s broader recovery from its lows. Previous earnings report referenced in background

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SOPH. BTIG Research restated a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, SOPHiA GENETICS has a consensus rating of “Hold” and a consensus price target of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.